Physician profile
Frederick Chaz Dolgin
NPI 1184681876
$501.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $89.18 · 2021: $77.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.09 | 2019 | |
| Novo Nordisk INC | $73.83 | 2019-2021 | |
| Pfizer INC. | $58.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $48.30 | 2019 | |
| Daiichi Sankyo INC. | $42.53 | 2019 | |
| Amarin Pharma, INC. | $33.49 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $30.58 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2021 | |
| Merck Sharp & Dohme LLC | $14.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2019 | |
| Horizon Therapeutics Plc | $13.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.74 | 2020 | |
| Currax Pharmaceuticals LLC | $11.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Dolgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.